University of Kentucky

UKnowledge
Internal Medicine Faculty Publications

Internal Medicine

1-1-2020

Gynecologic Large Cell Neuroendocrine Carcinoma: A Review
Grant Burkeen
University of Kentucky

Aman Chauhan
University of Kentucky, amanchauhan@uky.edu

Rohitashva Agrawal
University of Kentucky

Riva Raiker
University of Kentucky

Jill M. Kolesar
University of Kentucky, jill.kolesar@uky.edu

See next page for additional authors
Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub
Part of the Internal Medicine Commons, Oncology Commons, Pharmacy and Pharmaceutical
Sciences Commons, and the Surgery Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Burkeen, Grant; Chauhan, Aman; Agrawal, Rohitashva; Raiker, Riva; Kolesar, Jill M.; Anthony, Lowell B.;
Evers, B. Mark; and Arnold, Susanne, "Gynecologic Large Cell Neuroendocrine Carcinoma: A Review"
(2020). Internal Medicine Faculty Publications. 217.
https://uknowledge.uky.edu/internalmedicine_facpub/217

This Review is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been
accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For
more information, please contact UKnowledge@lsv.uky.edu.

Gynecologic Large Cell Neuroendocrine Carcinoma: A Review
Digital Object Identifier (DOI)
https://doi.org/10.1177/2036361320968401

Notes/Citation Information
Published in Rare Tumors, v. 12.
© The Author(s) 2020
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is
attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/openaccess-at-sage).

Authors
Grant Burkeen, Aman Chauhan, Rohitashva Agrawal, Riva Raiker, Jill M. Kolesar, Lowell B. Anthony, B.
Mark Evers, and Susanne Arnold

This review is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/217

968401
review-article2020

RTU0010.1177/2036361320968401Rare TumorsBurkeen et al.

rare
tumors

Review

Rare Tumors
Volume 12: 1–11
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
https://doi.org/10.1177/2036361320968401
DOI: 10.1177/2036361320968401
journals.sagepub.com/home/rtu

Gynecologic large cell
neuroendocrine carcinoma:
A review
Grant Burkeen1, Aman Chauhan2,3 , Rohitashva Agrawal2,
Riva Raiker1, Jill Kolesar3,4, Lowell Anthony2,3, B. Mark Evers3,5
and Susanne Arnold2,3

Abstract
Large cell neuroendocrine carcinomas (LCNEC) are rare, aggressive high-grade neuroendocrine neoplasms within the
neuroendocrine cell lineage spectrum. This manuscript provides a detailed review of published literature on LCNEC of
gynecological origin. We performed a PubMed search for material available on gynecologic LCNEC. We analyzed 104
unique cases of gynecologic LCNECs, of which 45 were cervical primary, 45 were ovarian, 13 were uterine, and 1 was
vaginal. A total of 45 cases of cervical LCNEC were identified with a median age of 36 years. Median overall survival was
16 months. We identified 45 ovarian LCNEC cases in the published literature with a median age of 54 years. Median overall
survival was 8 months. 13 LCNEC cases of uterine origin were identified; 12 out of 13 were of endometrial origin and the
median age was 71 years. The majority of patients presented with Stage III/IV disease (stages I–IV were 31%, 8%, 38%, and
23%, respectively). Gynecologic LCNEC is an aggressive malignancy. Our current understanding of the disease biology
is very limited. Efforts are required to better understand the genomic and molecular characterizations of gynecological
LCNEC. These efforts will elucidate the underlying oncogenic pathways and driver mutations as potential targets.
Keywords
Large cell neuroendocrine carcinoma, gynecologic LCNEC literature review, PubMed search
Date received: 3 May 2019; accepted: 30 September 2020

Introduction
Neuroendocrine tumors (NETs) are rare tumors that originate in cells of neuroendocrine lineage. NETs are classified
pathologically by their grade as well as their differentiation; therefore, the tumor types within this lineage range
from low to high grade but also from well differentiated to
poorly differentiated.1 High-grade neuroendocrine neoplasms, in particular, are a group of heterogeneous malignancies that can originate in any part of the body. Large cell
neuroendocrine carcinoma (LCNEC) is an aggressive subtype of high-grade neuroendocrine neoplasm. The most
common site of origin for LCNEC is the thorax; however,
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it has been reported in the gastrointestinal tract, biliary
tract, urogenital region, head, neck and the gynecologic
tract among others. Diagnosis depends on a definite pathology because prognosis and treatment varies drastically
between LCNEC and well-differentiated neuroendocrine
tumors. LCNEC pathology is characterized by an organoid,
trabecular, or cordlike growth pattern interspersed by
peripheral palisading, rosette clusters, and geographic
necrosis.2 There is also a high mitotic rate with a predominance of large cells with large vesicular nuclei and prominent nucleoli.2 The growth pattern for LCNEC follows
peripheral palisading and necrosis to a variable extent.
LCNEC is usually argyrophilic and normally shows positive reactivity for synaptophysin, CD56, or chromogranin.3
Chromogranin is a sensitive and specific serum marker for
low-grade neuroendocrine tumors, however its utility is
limited in high-grade neuroendocrine carcinomas (NEC).4
Anecdotal reports suggest that neuron-specific enolase is a
sensitive tumor marker for LCNEC and other high-grade
NEC, however NET/NEC serum tumor markers suffer
from lack of specificity and high variability and cannot be
considered diagnostic.5 Furthermore, adenocarcinoma,
squamous cell carcinoma or small cell carcinoma can coexist with LCNECs.6 As there are many cell types in the
female gynecologic tract, this large cell pathology is often
misdiagnosed. Regarding the prevalence of human papilloma virus (HPV) in gynecologic LCNEC, the presence of
HPV has been demonstrated in most reported cases of
LCNEC, ranging from 53% to 100% with the most common strains of virus being HPV16 and HPV18.7
This manuscript provides a detailed review of published
literature on LCNEC of gynecological origin. We discuss
the results and provide a management strategy for these
very rare malignancies.

Methods
We performed a PubMed search for material available on
gynecologic LCNEC. Search words included: “management of large cell neuroendocrine carcinoma” and “large
cell neuroendocrine carcinoma,” which resulted in 181 and
1969 publications, respectively. After additional filtering
using the terms “gynecologic,” “cervix,” “ovary” and
“uterus,” 53 publications were reviewed. Of these, 29 pertinent manuscripts were identified for detailed review after
removal of manuscripts not discussing case reports or not
including relevant information necessary for this review.

Results
Cervical LCNEC: A total of 45 cases of cervical LCNEC
were identified, with a median age of 36 years (range 21–
75 years). Our summary of cervical LCNEC is reported in
Table 1. The median age at presentation was 36 years (range
21–75). Patients were staged I (51%), II (22%), III (9%),
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and IV (9%), therefore most were early stage. The remaining four patients (9%) did not have a stage identified. Of the
45 patients, 76% received surgery management, with most
receiving either radical or total abdominal hysterectomy. In
this cohort, 69% of patients received systemic platinumbased chemotherapy and 47% of patients received radiation
therapy. Outcomes varied significantly. Mortality related to
cervical LCNEC was reported as 47% at the time of publication. Survival ranged from 2 weeks post-operative to
44 months. Median overall survival (OS) was 16 months;
per stage median survival was 18.5, 12, 21, and 1 month for
stages I, II, III, and IV, respectively. For the stage III disease cohort, Tangjitgamol et al. reported a case with a
44-month survival, thus explaining the increased survival.8
Survival ranged from 0.5 to 151 months (no survival data
was available for 11% of patients).
Ovarian LCNEC: We identified 45 unique ovarian
LCNEC cases in the published literature, and these are summarized in Table 2. The median age at presentation was
54 years. Epithelial components that were associated with
these malignancies included mucinous borderline tumor,
mucinous adenocarcinoma, mucinous adenoma/cystadenoma, endometrioid adenocarcinoma and those with mixed
or otherwise unspecified features. The majority of ovarian
LCNECs were unilateral. Most patients were diagnosed at
an early stage with stages I, II, III, and IV at 33%, 7%, 22%,
and 24%, respectively. The remaining six patients did not
have a stage reported. Of significance, all patients received
surgery and 87% also received chemotherapy. In this cohort,
of the 39 patients that received some form of chemotherapy;
34 received platinum-based therapy and the remaining five
did not specify the form of chemotherapy. At publication,
56% of patients had died of the disease. Median overall survival was 8 months; stratified OS for stages I to IV was 9.5,
22.5 (n = 3 for this group), 8 and 8 months, respectively.
Outcome data was not available for two patients. Stage II
disease represents 3 of the 45 cases; survival of one case
was not available. Oshita et al. reported a survival of
40 months in one patient with stage II disease, thus explaining the increased median survival of this cohort.9 Of all the
patients, survival ranged from 0 to 68 months.
Uterine/Vaginal LCNEC: We found 13 LCNEC cases of
uterine origin as described in Table 3; 12 of the 13 were
endometrial in origin and the remaining one was of uterine
corpus origin. Median age at presentation was 71 years.
Unlike previous cohorts, the majority of patients presented
with stage III/IV disease. The percentage among stages
I-IV were 31%, 8%, 38%, and 23%, respectively. 12
patients (92%) received surgery and 6 (46%) received
chemotherapy. For the patients that received chemotherapy,
a platinum-based therapy was employed in all cases; three
patients received carboplatin plus etoposide, two patients
received cisplatin+irinotecan, and one patient received
carboplatin+paclitaxel. In this cohort, 6 of 13 patients
received radiation therapy. The percentage of patients with
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Table 1. Cervical large cell neuroendocrine carcinomas reported in the literature.
Origin

Presentation

Age

Stage

Surgery

Treatment

Response (duration) Authors
(Reference)

Cervix

Post-fibroid
myomectomy
surgery
Routine
screening

48

IV

None

RT, nivolumab + sandostatin

AWD (12 months)

Shahabi et al.4

27

IA

Cisplatin + etoposide

NED (6 months)

Rajkumar25

Cervix

N/A

30

IIB

Radical
abdominal
trachelectomy,
PLD
None

NED (23 months)

Li26

Cervix
Cervix
Cervix
Cervix
Cervix
Cervix
Cervix
Cervix

31
34
27
51
47
42
31
40

IB
IB
IB
IB
IB
IIA
IA
IB

AWD (151 months)
DOD (19 months)
DOD (16 months)
DOD (16 months)
NED (12 months)
DOD (6 months)
NED (10 months)
NED (9 months)

Sato et al.17
Sato et al.17
Sato et al.17
Sato et al.17
Sato et al.17
Sato et al.17
Yun27
Kawauchi28

Cervix

Vaginal bleeding
Vaginal bleeding
Vaginal bleeding
Vaginal bleeding
Abnormal Pap
Abnormal Pap
N/A
Atypical vaginal
bleeding
Vaginal spotting

RT and brachytherapy;
Etoposide + cisplatin
TAH, BSO
RT, chemo
TAH, BSO
RT, chemo
TAH, BSO
RT, chemo
TAH, BSO
RT, chemo
TAH, BSO
RT, chemo
TAH, BSO
RT, chemo
RH
NFT
TAH, BSO, PLD NFT

47

IIA

RH, PPALD

NED (6 months)

Cetiner et al.12

Cervix

Screening Pap

25

IB1

RH, PPALD

Initial partial
response then
DOD (35 months)

Krivak et al.15

Cervix

Post-coital
bleeding
Vaginal bleeding
most common
N/A
N/A
N/A
N/A
Vaginal bleeding

36

IIA

None

IIB

None

Progression, DOD
(33 months)
AWD (1 months)

Krivak et al.15

55

RT and brachytherapy (patient
could not afford chemo)
INITIAL: Etoposide + cisplatin;
RECURRENCE: Vincristine,
adriamycin + cytoxan;
carboplatin + etoposide;
THEN: Topotecan; THEN:
Paclitaxel; THEN: Protein
kinase C inhibitor
RT, concurrent
etoposide + cisplatin
NFT

75
51
65
42
51

IIIB
IVB
IVB
N/A
IIA2

Rhemtula29
Rhemtula29
Rhemtula29
Rhemtula29
Omori et al.7

31

N/A

RT
NFT
RT
NFT
Irinotecan + cisplatin prior to
surgery cisplatin
Cisplatin + irinotecan

DOD (3 months)
DOD (0.5 months)
DOD (1 months)
N/A
NED (21 months)
NED (15 months)

Tanimoto30

33

IB

NED (24 months)

Yoseph31

37

IIIB

RH, BSO,
PPALD
Unknown

Cisplatin + etoposide

Cervix

Post-coital
bleeding
6 week postpartum check
N/A

None
None
None
None
RH, BSO,
bilateral PLD
RH

Unknown

DOD (21 months)

Cervix

N/A

55

IIA

Unknown

Unknown

DOD (12 months)

Cervix
Cervix

N/A
Pelvic pain and
vaginal bleeding
N/A
N/A
Abnormal Pap

38
31

IB
IIIB

Chemo + radio-chemo
Chemo, RT

AWD (21 months)
N/A

60
40
24

N/A
IVB
IB2

TAH, BSO
TAH, BSO,
PPALD
RH
None
TAH

Kajiwara
et al.18
Kajiwara
et al.18
Baykal32
Powell33

Chemo, RT
Platinum based chemo
Concurrent cisplatin + RT;
THEN: Etoposide + cisplatin +
doxorubicin; THEN: Oral
etoposide; Brachytherapy also
used

DOD (18 months)
N/A
NED (47 months)

Markapoulos34
Brown35
Embry et al.14

Cervix

Cervix
Cervix
Cervix
Cervix
Cervix
Cervix
Cervix
Cervix

Cervix
Cervix
Cervix

Rhemtula29

(Continued)
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Table 1. (Continued)
Origin

Presentation

Age

Stage

Surgery

Cervix
Cervix
Cervix
Cervix
Cervix
Cervix
Cervix

Abnormal Pap
Abnormal Pap
Abnormal Pap
Vaginal bleeding
Vaginal bleeding
Vaginal bleeding
Vaginal bleeding

36
35
33
31
62
38
31

IA2
IB
IB
IB
IIA
IA2
IB

RH
RH
RH
RH
RH
RH
RH

Cervix
Cervix
Cervix

N/A
N/A
N/A

29
36
21

IB
IB
IB

Cervix

N/A

29

IB

Cervix
Cervix
Cervix

N/A
25
Vaginal bleeding 37
N/A
42

IB
N/A
III

Cervix

Abnormal Pap

45

IIB

Cervix

Post-coital
vaginal bleeding

35

IIB

Treatment

NFT
Etoposide + cisplatin + RT
Chemo
Chemo
NFT
N/A
Adriamycin, vincristine,
cyclophosphamide
RH
NFT
RH
Cisplatin, etoposide, RT
RH
Cisplatin, etoposide,
adriamycin
RH
Cisplatin, etoposide,
adriamycin
RH
Carboplatin, etoposide
RH
Chemo, RT
Extrafascial
Paclitaxel + carboplatin
hysterectomy,
(patient declined RT);
BSO, and partial RECURRENCE: Re-induction
OMY
paclitaxel carboplatin, then
cisplatin and etoposide
RH, BSO and
RT, brachytherapy, and
PLD
concurrent cisplatin
TAH, RSO
Cyclophosphamide,
adriamycin, cytoxan, cisplatin,
etoposide, RT adjuvant therapy
with ifosfamide, cisplatin, and
etoposide

Response (duration) Authors
(Reference)
NED (36 months)
DOD (18 months)
DOD (8 months)
NED (36 months)
DOD (6 months)
LFU
DOD (12 months)

Gilks et al.16
Gilks et al.16
Gilks et al.16
Gilks et al.16
Gilks et al.16
Gilks et al.16
Gilks et al.16

DOD (24 months)
DOD (24 months)
DOD (10 months)

Gilks et al.16
Gilks et al.16
Gilks et al.16

NED (30 months)

Gilks et al.16

NED (6 months)
N/A
DOD (44 months)

Gilks et al.16
Niwa36
Tangjitgamol
et al.8

NED (unknown)

Dikmen37

DOD (19 months)

Tsou et al.1

AWD: alive with disease; BSO: bilateral salpingo-oophorectomy; Chemo: non-specified chemotherapy; DOD: dead of disease; LFU: lost to follow
up; N/A: not available; NED: no evidence of disease; NFT: no further treatment; OMY: omenectomy; PLD: pelvic lymph node dissection; PPALD:
pelvic and para-aortic lymph node dissection; RH: radical hysterectomy; RSO: right salpingo-oophorectomy; RT: radiation therapy; TAH: total
abdominal hysterectomy.

uterine LCNEC that died of disease was 46%. Median OS
was 7.5, 23 (n = 1), 10 and 1 month for stages I-IV, respectively, with survival ranging from 1 month to 23 months.
Jin et al. reported one case of a 53-year-old female that was
diagnosed with stage IV vaginal LCNEC. She was treated
with palliative chemotherapy and radiation and was alive
with disease at 12 months.10
Tables 1–3 summarize the individual case-based data for
cervical, ovarian, uterine and vaginal LCNEC, respectively.

Discussion
Neuroendocrine neoplasms of the gynecologic tract are
particularly uncommon with NETs of the uterus or cervix
representing 0.9% to 1.5% of the tumors and accounting
for 100 to 200 diagnoses yearly in the United States.11
Furthermore, with the potential ambiguity surrounding
the diagnostic criteria, some LCNEC cases may have been
inaccurately classified as undifferentiated or poorly differentiated adenocarcinoma. Large cell carcinomas of the

gynecologic tract are especially aggressive, tend to recur,
and there is limited data regarding the natural history, progression, and management of the disease. Due to the rare
nature of the disease, it is challenging to determine an
optimal therapy by utilizing randomized controlled trials,
but it has been proposed that these patients could be
treated similar to those with small-cell neuroendocrine
carcinoma because of similar malignant potential and
platinum sensitivity.12 For therapeutic intervention, a
multi-modality approach should be undertaken.
For our review, the 104 unique cases of gynecologic
LCNECs were positive for neuroendocrine markers, such
as chromogranin A, CD56 and synaptophysin. Of the 45
cases of LCNEC of the cervix, an abnormal screening
Papanicolaou smear and vaginal bleeding were the most
common reasons for presentation. For the majority of ovarian LCNEC cases, abdominal pain and/or abdominal distention were the reasons for presentation, whereas
post-menopausal bleeding was the most common reason
for presentation for endometrial and uterine LCNEC. The

77
58

Abdominal discomfort

Ovary – Mucinous
Ovary – Mucinous

Ovary – Mucinous AdCa
Ovary – Mucinous AdCa
Ovary – Mucinous AdCa
Ovary – Mucinous AdCa
Ovary – Mucinous Intraepithelial
AdCa
Ovary – Mucinous AdCa +
Teratoma
Ovary – Mucinous AdCa +
Teratoma
Ovary – Serous AdCa
68

Abdominal distention
and ascites
Abdominal pain
Abdominal pain
39
55

53

Abdominal distention

58
77

71

53

Abdominal pain and
distention
N/A
N/A

Ovary – Serous AdCa

35
64

Abdominal mass

Abdominal distention
Abdominal discomfort

Ovary
Ovary – Pure

27
76
46

36
45
68
73
44

Pelvic mass
Abdominal pain
Abdominal distention

Ovary – Pure
Ovary
Ovary – Pure

40

67
50

68

N/A
N/A
N/A
N/A
N/A

Abdominal distention,
pain, fever, itching

Ovary – Pure

Ovary – Mucinous AdCa
Ovary – Endometroid AdCa

Urinary frequency
Abdominal distention

Ovary
Ovary – Mucinous Adenoma

Ovary – Undifferentiated NonSmall Cell
Ovary – Undifferentiated NonSmall Cell

Ovary – AdCa

35

Abdominal pain and
amenorrhea
Abdominal distention
and pain
Abdominal distention

Ovary

Age

Presentation

Origin (and associated cells)

IV
I

IV

I

IV

IA
IB
IIB
IIIC
IA

IIIB
IA

IIIB

N/A
IA

IC
N/A
IIIC

IIIC

IIB
IA

IA

IV

IV

IIIC

Stage

TAH, BSO
TAH, BSO

TAH, BSO, OMY, debulking

TAH, BSO, OMY

TAH, BSO, OMY, PLD

TAH, BSO
TAH, BSO, OMY
TAH, BSO, OMY
Prior TAH, BSO, OMY
TAH, BSO, OMY

TAH, BSO, OMY
RSO, prior TAH

TAH, BSO

BSO, OMY, PPALD 9 mo
after laparoscopic type I
hysterectomy, bilateral PLD
LSO, OMY
TAH, BSO, OMY
Subtotal abdominal
hysterectomy, BSO, OMY
TAH, BSO, OMY
TAH, BSO + OMY

TAH, BSO, OMY, PPALD
TAH, BSO, OMY + PLD

TAH, BSO, OMY, PLD

Surgical debulking

TAH, BSO, OMY, PPALD

TAH, BSO

Surgery

Table 2. Ovarian large cell neuroendocrine carcinomas reported in the literature.

DOD (7 months)

Cisplatin + etoposide
Carboplatin + paclitaxel

AWD (8 months)
NED (68 months)

DOD (7 months)

Carboplatin + paclitaxel

Cisplatinum-based chemo
Cisplatinum-based chemo

DOD (3 months)

N/A
Chemo
N/A
Paclitaxel, cisplatin, adriamycin
Paclitaxel, carboplatin

NED (8 months)

DOD (4 months)
NED (9 months)

NED (10 months)
Died post-op
DOD (4 months)

DOD (8 months)
DOD (19 months)
with Mets
Unknown
DOD (36 months)
Unknown
DOD (8 months)
DOD (4 months)

Chemo
RT

Chemo
Bleomycin, cisplatin + etoposide;
Bleomycin discontinued due to
development of side effects
Taxol + carboplatin

Chemo
NFT
Paclitaxel + carboplatin

(Continued)

DraganovaTacheva49
Veras et al.23
Veras et al.23

Chenevert48

Chenevert48

Eichorn47
Eichorn47
Eichorn47
Chen20
Chen20

Eichorn47
Eichorn47

Choi46

Kim
Lindboe45

Behnam43
Aslam44
Tsuji et al.11

Shakuntala42

Ki40

NED (6 months)

DOD (17 months)

INITIAL: Cisplatin + paclitaxel;

Ki40

Ki40
Asada41

Died (1.5 months)

Etoposide + carboplatin

Cokmert39

Agarwal38

Authors
[Reference]

AWD (5 months)
DOD (7 months)

DOD (7 months)

Etoposide + cisplatin

RECURRENCE: Docetaxel
Carboplatin + paclitaxel
INITIAL: Cisplatin + etoposide;
RECURRENCE: Paclitaxel + carboplatin
Etoposide + cisplatin

AWD (3 months)

Response
(Duration)

NFT

Treatment

Burkeen et al.
5

69

40

65
42

80

66

73

IV

N/A

IC
IIIB

IIC

IV

IV

N/A

IC

III
I

IV

TAH, BSO, PLD, OMY,
APPY
TAH, BSO, OMY
TAH, BSO, peritoneum
resection of Douglas pouch,
OMY, PLD
BSO, OMY, sigmoid colon
debulking
debulking

LSO, partial OMY; THEN:
TAH, RSO, PPALD
TAH with bilateral
adnexectomy, left-sided
nephrectomy, OMY
TAH, BSO, OMY

TAH, BSO, OMY, PLD,
APPY
TAH, BSO, OMY

TAH, RSO
BSO
RSO, APPY
TAH, BSO, OMY, PLD

TAH, BSO
TAH, BSO

BSO, OMY, APPY

TAH, BSO
TAH, BSO
TAH, BSO

Surgery

DOD (4 months)
NED (12 months)

NED (64 months)

NED (40 months)
DOD (2 months)
NED (32 months)

NED (6 months)

Irinotecan + nedaplatin
Carboplatin + paclitaxel
INITIAL: Carboplatin + paclitaxel
RECURRENCE: Brain RT
Carboplatin + paclitaxel
Carboplatin + paclitaxel
Carboplatin + paclitaxel
Etoposide + cisplatin

DOD (6 months)

DOD (8 months)

Cisplatinum + cyclophosphamide

Paclitaxel + carboplatin

DOD (10 months)

DOD (2 months)
NED
(66 months)
DOD (9 months)
NED (28 months)
DOD (3 months)
NED (6 months)

DOD (36 months)

DOD (20 months)
NED (37 months)
NED (11 months)

Response
(Duration)

NFT

Cisplatinum-based chemo
Cisplatinum-based chemo
Cisplatinum-based chemo
Chemo

Cisplatinum-based chemo
Cisplatinum-based chemo

Cisplatinum-based chemo

Cisplatinum-based chemo
Cisplatinum-based chemo
Cisplatinum-based chemo

Treatment

Miyamoto53

Shakuntala42

Oshita et al.9
Oshita et al.9

Oshita et al.9

Oshita et al.9

Dundr et al.22

Ohira52

Collins et al.21

Jones51

Veras et al.23
Veras et al.23
Veras et al.23
Yasuoka50

Veras et al.23
Veras et al.23

Veras et al.23

Veras et al.23
Veras et al.23
Veras et al.23

Authors
[Reference]

AdCa: adenocarcinoma; APPY: appendectomy; AWD: alive with disease; BSO: bilateral salpingo-oophorectomy; Ca: carcinoma; Chemo: non-specified chemotherapy; DOD: dead of disease; LMP: low malignant potential; LSO: left
salpingo-oophorectomy; Mets: metastases; N/A: not available; NED: no evidence of disease; NFT: no further treatment; OMY: omenectomy; PLD: pelvic lymph node dissection; PPALD: pelvic and para-aortic lymph node dissection;
RSO: right salpingo-oophorectomy; RT: radiation therapy; TAH: total abdominal hysterectomy.

Ovary – Mature Cystic
Teratoma

Ovary – Pure

Abdominal pain and
distention
Unknown

Asymptomatic pelvic
mass
Abdominal pain
Abdominal mass

Ovary – Endometroid AdCa

Ovary – Endometroid AdCa
Ovary –Endometroid AdCa

Asymptomatic pelvic
mass

Ovary- Pure

Ovary – Pure

33

Abdominal pain,
fatigue
Dysarthria

65
34

63
59
22
36

Ascites
Abdominal pain
Abdominal pain
Abdominal distention
and weight loss
Abdominal distention

Abdominal distention

N/A

55
54

Vaginal bleeding
Pelvic mass

Ovary – Mucinous Cystadenoma
and Mucinous AdCa
Ovary – Endometrioid Adca

IV
I
I
N/A

25

Abdominal pain

IV
III
III

42
53
47

Pelvic pain
Ascites
Abdominal bloating

Stage

Ovary – none
Ovary – Endometroid Ca
Ovary – AdCa and Mature
Teratoma
Ovary – Mature Cystic
Teratoma
Ovary – Mucinous LMP
Ovary – Mucinous and
Endometroid Ca
Ovary – Endometroid
Ovary – AdCa
Ovary – Mucinous Ca
Ovary – Mucinous Intraepithelial
Ca
Ovary – Mucinous Cystadenoma

Age

Presentation

Origin (and associated cells)

Table 2. (Continued)
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Table 3. Endometrial, uterine corpus and vaginal large cell neuroendocrine carcinoma reported in the literature.
Origin (plus
Presentation
associated cells)
Endometrium –
Pure
Endometrium –
Sarcomatoid
Endometrium –
Pure
Endometrium –
Endometroid
Endometrium –
Endometroid
Endometrium –
Endometroid
Endometrium –
Endometroid
Endometrium
Endometrium

Age

Stage

Surgery

Treatment

Response
(duration)

Authors
(Reference)

IVB

NFT

DOD (1 months)

Nguyen et al.5

NFT

AWD (16 months) Terada54

RT, cisplatin, etoposide

AWD (12 months) Mulvany55

NFT

DOD (5 months)

Mulvany55

Postmenopausal 71
vaginal bleeding
Abnormal
40
uterine bleeding
N/A
50

IB

N/A

80

IC

RH, BSO, OMY,
PPALD
TAH, BSO,
OMY, PLD
TAH, BSO,
OMY
TAH, BSO

N/A

77

IIB

TAH, BSO

RT

DOD (23 months)

Mulvany55

N/A

79

IIIA

RT

AWD (2 months)

Mulvany55

N/A

88

IIIC

RT

AWD (1 months)

Mulvany55

Abdominal
distention
Vaginal bleeding

73

IVB

TAH, BSO,
Omental biopsy
TAH, BSO, LN
biopsy
None

Patient refused

DOD (1 months)

Makihara34

73

IIIC

TAH, BSO,
OMY, PPALD
TAH, BSO,
OMY, PPALD

Cisplatin + irinotecan

AWD (13 months) Makihara34

IIIC

Endometrium

Postmenopausal 59
bleeding

IV

Endometrium –
Pure
Endometrium –
Pure
Uterine
Corpus – Pure

Post-menopausal 70
bleeding
N/A
42

IB

Vagina

Pelvic pain and
53
difficulty voiding

Lower
abdominal pain

52

IC

TAH, BSO,
OMY
RH

IIIC2

TAH, BSO,
PPALD

IV

None

Carboplatin + paclitaxel DOD (12 months)
with RT and
brachytherapy;
THEN: Pegylated
doxorubicin followed
by etoposide, cisplatin
and LAR
Cisplatin + etoposide
NED (6 months)

Shahabi et al.4

Cisplatin + etoposide

AWD (9 months)

INITIAL:
Irinotecan + cisplatin
with RT
PROGRESSION: RT,
paclitaxel + carboplatin
Palliative
radiation + chemo

DOD (10 months)

AlboresSaavedra et al.3
Kobayashi
et al24

Deodhar56

AWD (12 months) Jin et al.10

AWD: alive with disease; BSO: bilateral salpingo-oophorectomy; Chemo: chemotherapy; DOD: dead of disease; LAR: long acting-release
octreotide; LN: lymph node; N/A: not available; NED: no evidence of disease; NFT: no further treatment; OMY: omenectomy; PLD: pelvic lymph
node dissection; PPALD: pelvic and para-aortic lymph node dissection; RH: radical hysterectomy; RT: radiation therapy; TAH: total abdominal
hysterectomy.

one case of LCNEC of the vagina reported by Jin et al. was
of a 53-year-old female who presented with metastatic
stage IV disease.10
LCNEC of the gynecologic tract has a poor prognosis,
especially for patients that present in an advanced stage. A
variety of therapeutic regimens exist with attention toward a
multimodality approach, including combinations of surgery,
chemotherapy and radiation. This multimodal approach is
supported by both the Society of Gynecologic Oncology
and the Gynecologic Cancer Intergroup.13 Survival outcome
is variable and dependent on both stage at diagnosis and
response to the treatment. Embry et al. reported that earlier

stage (p < 0.00001) and the addition of chemotherapy (p =
0.04) were associated with improved survival for cervical
LCNECs.14 They also reported platinum agents (p = 0.034)
and platinum+etoposide (p = 0.027) were associated with
improved survival.14 Furthermore, for LCNECs with metastatic lesions, long-term survival is uncommon.15 Because
of the rarity of these malignancies, management is often
extrapolated from small and large cell carcinomas of the
lung. Adjuvant chemotherapy with cisplatin, carboplatin,
etoposide or cyclophosphamide has been used in the management of LCNEC of the lung, and is very frequently used
in LCNEC of the gynecologic tract as well.4
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Cervix
Our 45 cases of cervical LCNEC summarized in Table 1
include patients with all stages of disease as well as a wide
range of survival (0.5 months to 151 months). Treatment
included surgery, chemotherapy, and/or radiation, with a
majority (76%) receiving surgery. Of note, Embry et al.
reported 62 cases of cervical LCNEC; importantly, the
authors documented a similar median age to ours (37 years)
with the identical age range of 21 to 75. Furthermore, a
majority of their patients also had stage I disease. Of these
cases, 73% underwent primary surgery, 4.7% underwent
primary radiation, 4.7% underwent chemotherapy and 8%
had chemoradiation. There were 9.6% with no primary
treatment. Reported patient outcomes were as follows:
58% died of disease, 26% had no evidence of disease, 3%
were alive with disease and 13% had no survival data.
Multivariate analysis revealed that earlier stage (p <
0.00001) and the addition of chemotherapy (p = 0.04)
particularly platinum agents (p = 0.034) and the
platinum+etoposide combination (p = 0.027) were associated with improved survival.14
For early stage cervical LCNEC, therapy should begin
with radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy. Gilks et al. reported a
case of a 36-year-old patient with stage I disease who had
no evidence of it 36 months after a radical hysterectomy.16
However, the current recommendation is to follow surgery
with chemoradiation, cisplatin (platinum-based therapy)
and etoposide.13 Of note, this therapy is based on regimens
used in small cell lung cancer as there are no prospective
phase II or phase III clinical trials evaluating anti-tumor
efficacy in gynecologic LCNEC. However, prophylactic
brain irradiation is not recommended in these patients as it
is with small cell lung cancer.
For locally advanced disease in women with neuroendocrine carcinoma (stage IB2–IVA disease), concurrent chemradiation followed by additional chemotherapy with intent
to cure should be the treatment plan. The ideal regimen is
the same as that described above, with cisplatin and etoposide given on a 3-week cycle. Sato et al. implemented
chemotherapy (specific therapy not identified) with concurrent radiation therapy after a total abdominal hysterectomy and bilateral oophorectomy in a 31 to year-old patient
with stage 1B disease; this patient was reported to be alive
with disease at 151 months.17 For patients with no evidence
of intraperitoneal spread and nodal metastatic burden, neoadjuvant chemotherapy with cisplatin and etoposide followed by consolidation radiation therapy may be of some
benefit.13 However, per our analysis, LCNEC remains a
disease with poor prognosis, with a median OS of less than
2 years.
Hormone receptor and growth factor receptor expression could have a role in predicting survival in cervical
LCNEC. Tangjitgamol et al. performed this evaluation for
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cervical LCNEC and identified a significantly shorter OS
in patients with a HER-2 neu negative status as compared
to those with positive HER-2 neu tumors (median OS: 14.2
vs 33.1 months), and a trend towards a worse OS in patients
positive for epidermal growth factor receptor.8 The group
concluded that the combination of negative HER-2 neu status and positive epidermal growth factor receptor expression impaired OS.8
There is a potential role for targeted therapy in cervical
LCNEC. Somatostatin receptors are profusely expressed in
low-grade NETs, and some somatostatin receptor binding is
generally observed in high-grade NEC. Hence targeted therapy with octreotide, a somatostatin analog, could be explored
as suggested by Shahabi et al. Potential mechanisms by
which octreotide could inhibit tumor growth include inhibition of growth hormone secretion, such as IGF-1, inhibition
of angiogenesis, and through direct action on the tumor.4
Kajiwara et al. also proposed using octreotide to treat neuroendocrine tumors, since 3 out of 7 cases (2 of 5 small cell
carcinomas and 1 of 2 LCNEC) expressed somatostatin
receptor type 2A.18 However, a larger study is needed to validate these conclusions. Many clinicians are skeptical of the
role for somatostatin analog in LCNEC management.
The role of radiation therapy should be strongly considered, especially with the addition of brachytherapy in the
setting of LCNEC of the cervix. Robin et al. found a significant improvement in OS when brachytherapy and external beam radiation therapy were combined. They identified
100 patients with locally advanced non-metastatic neuroendocrine cervical cancer (included both large cell and small
cell) that were treated with definitive chemoradiotherapy
between 2004 and 2012. There was a substantial improvement in OS when brachytherapy was administered in addition to external beam radiotherapy. By multivariate
analysis, an improved median survival of 48.6 versus
21.6 months (95% CI, 0.255–0.883; p = 0.019) was seen
with the addition of brachytherapy compared to external
beam radiotherapy alone. This study was performed in
patients with locally advanced neuroendocrine carcinoma
of the cervix, of both large and small cell etiology, treated
with chemoradiotherapy.19

Ovary
As evidenced by our 45 cases of ovarian LCNEC summarized in Table 2, patients with this disease unfortunately
have a poor prognosis; 8 month survival was noted for
those patients with both stage III and stage IV disease.
Reported survival for all stages ranged from 0 to 68 months.
In the 33 cases reported by Oshita et al., the 5-year survival
was only 34.9%.9 One case exhibited rapid disease progression with pelvic mass formation, liver metastasis and pelvic
lymphadenopathy within 2 weeks after primary surgery,
with the tumor being unresponsive to Taxol and carboplatin
chemotherapy.9 Evidence that ovarian LCNEC is an

Burkeen et al.
aggressive malignancy has also been reported in other cases
outlined above.20,21 However, it is worth noting that there is
evidence of success with surgery followed by adjuvant
platinum-based chemotherapy. Dundr et al. reported a case
of a 73-year-old with stage IV ovarian LCNEC and no evidence of the disease 12 months after undergoing surgery
and chemotherapy with carboplatin and paclitaxel.22 An
anecdotal case series from MD Anderson Cancer Center
reported 22 to 68 months survival in three stage I cases with
standard surgery followed by adjuvant platinum-based
chemotherapy.23 Based on the above-mentioned observations, therapeutic consideration similar to primary lung
LCNEC can be applied toward those of ovarian origin. This
includes utilizing such regimens as cisplatin/vinorelbine,
cisplatin/etoposide, cisplatin/vinblastine, cisplatin/gemcitabine and cisplatin/docetaxel in tumors that are initially
unresponsive to first line taxotere and cyclophosphamide
therapy.9 In one case reported by Oshita et al., radiation was
utilized for brain metastasis and the patient had no evidence
of the disease for 64 months, which adds support to employing radiation in situations of local recurrence or distant
metastasis.9

Uterus
Limited data exists to guide therapy in cases of uterine
LCNEC, however as mentioned above, a multi-modality
approach is commonly applied. Similar to LCNEC of the
cervix, tumors in the uterus, notably the endometrium, are
managed initially with cytoreductive surgery. Based on
prior published reports, a hysterectomy and bilateral
salpingo-ophorectomy are recommended at minimum.5
Unfortunately, a number of cases were reported with
early-stage disease at the time of surgery that developed
distant metastasis or rapid recurrence; therefore, omentectomy and pelvic and paraaortic lymphadenectomy should
be considered for accurate staging. Of note, physicians
may want to determine a patient’s response to chemotherapy prior to initiating surgery, as surgery has often been
shown to be of little benefit. Currently there is no consensus regarding optimal management of these tumors after
surgery. In the case reports as described, adjuvant chemotherapy and/or radiation was either performed or planned
in the majority of the cases. Chemotherapy, radiation or
both is favored by most treating physicians. Occasionally,
neoadjuvant therapy is considered in cases where LCNEC
is diagnosed on a preoperative curettage, or when an
endometrial biopsy specimen is done in advanced cases of
ovarian cancer. Adjuvant chemotherapy generally consists of platinum and etoposide based chemotherapy as in
cervical disease.5 Shahabi et al. incorporated octreotide
into their treatment regimen due to a single case report of
its use for an endometrial small cell NET in which a partial response was reported; however, disease progression
was observed.4 In the one case of LCNEC of the uterine
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corpus, Kobayashi et al. reported a rapidly progressing
stage III disease that did not respond to irinotecan/cisplatin initially but paclitaxel/carboplatin with concurrent
radiation was helpful.24

Conclusion
As discussed above, LCNECs are high-grade neuroendocrine carcinomas and represent a rare diagnosis, especially
in sites such as the gynecologic tract. Our current understanding of the biology of this pathology is limited. As
inadequate data exists regarding the treatment of this
pathology, it has been demonstrated in the aforementioned
cases of LCNEC in the gynecologic tract that a multimodality treatment approach including surgery, chemotherapy
and radiation should be undertaken. Further efforts are
required to gain more knowledge on how best to treat these
aggressive malignancies.
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